more

Related Articles

Sprint Closes $480M Deal for Wireless Spectrum
SSE Grabs Scottish Wind Farm
Aridis Pharma Picks Up Kenta Biotech’s Anti-Infection Products
Alliant, Bellisio Foods, TransDigm
Perficient Buys Salesforce Support Co.

SLIDESHOW

The M&A Scene: CEO Leadership
Dealmakers gathered at the Harvard Club in New York on May 7 as part of ACG NY's CEO Leadership event. Peter Gonye, a co-leader within Spencer Stuart's private equity practice in North America was the keynote speaker. Panelists included M. Tatum Pursell, senior adviser, Unlimited Horizons; Tony Ecock, general partner, Welsh Carson Anderson & Stowe; Jim Follett, former CEO of Authentic Response Inc.; Doron Grosman, operating partner, Court Square Capital; and Joelle Marquis, partner, Arsenal Capital.

Watercooler

3Qs With... Chris Randall, executive vice president, NBH Capital Finance
NBH Capital Finance will focus on the lower middle market

Dealmakers

Time Inc. -Meredith Pairing Would Have Been Too Complicated, Says Jeff Bewkes in Keynote
The Time Warner chairman hints there may be a future deal for the spun-off magazine business, maybe even with Meredith

Columns

The Buyside:
Trench Dealfare
Strategic players in the aerospace and defense sector look to offset losses by remaining on the hunt for targets

Today's Transactions:Gilead Sciences Buys YM BioSciences for $510M

The target has been developing a medication to treat myelofibrosis, a bone marrow disorder

By ALLISON COLLINS
December 12, 2012

Gilead Sciences Inc. (Nasdaq: GILD) will acquire YM BioSciences Inc. (NYSE: YMI) for about $510 million.

The deal amounts to about $2.95 per share.

YM is in the testing phases for a medication that could help patients with myelofibrosis, a bone marrow disorder. The disorder causes bone marrow to be replaced by scar tissue, which makes it difficult for the bone marrow to produce blood cells, which can lead to anemia, low blood-platelet count and spleen enlargement.

Foster City, Calif.-based Gilead is a biopharmaceutical company that commercializes and develops medications.

Other recent pharmaceutical deals include Pernix Therapeutics Holdings Inc.’s (NYSE: PTX) purchase of Somaxon Pharmaceuticals Inc. (Nasdaq: SOMX) in a $25 million all-stock deal, Nuron Biotech’s acquisition of vaccine Meningitec, and Pfizer Inc.’s (NYSE: PFE) NextWave Pharmaceuticals Inc. purchase.

 

For more information on related topics, visit the following: